Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5248482 | 0.90 | MEN1 (0.55) | MEN1KMT2AMAPTTDP1HPGD | |
| SCHEMBL13158518 | 0.89 | MAPT (0.61) | MEN1KMT2AMAPTTDP1HPGD | |
| SCHEMBL3108441 | 0.81 | CCR1 (0.47) | MEN1KMT2AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL3109778 | 0.79 | CCR1 (0.38) | MEN1KMT2AMAPTHPGDALDH1A1 | |
| SCHEMBL3110924 | 0.78 | HPGD (0.46) | MEN1KMT2AMAPTHPGDSMN1; SMN2 | |
| SCHEMBL3116707 | 0.77 | P2RX3 (0.47) | MAPTHPGDALDH1A1 | |
| SCHEMBL3115976 | 0.77 | CYP1A2 (0.47) | MEN1KMT2AMAPTHPGDSMN1; SMN2 | |
| SCHEMBL3110541 | 0.77 | MAPK14 (0.47) | MEN1KMT2AHPGDPOLBALDH1A1 | |
| SCHEMBL3112533 | 0.76 | SMN1; SMN2 (0.44) | MEN1KMT2AMAPTHPGDSMN1; SMN2 | |
| SCHEMBL5250837 | 0.76 | SMN1; SMN2 (0.54) | MEN1KMT2AMAPTTDP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803822-B2 | Triazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-28 | — | — | US | disclosed |
| US-20090105253-A1 | Triazole Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1867331-A1 | TRIAZOLE DERIVATIVE AND THE USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105253-A1 | Triazole Derivative and Use Thereof | F2R, HRH4, F2RL3 | MEN1 1111/4885KMT2A 2286/4885MAPT 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.